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A haemoprotein (Mr - 40 000) made up of two apparently identical subunits, and having Soret maximum 
at 405 nm, but displaying it mostly at about 410 nm or often at 415 nm in crude extracts owing to different 
bound small molecules, found in platelets of several species, has been purified from calf platelets. The puri- 
fied protein could bind the stable PGH2 analogue, U-46619, without co-operativity (h = 1 .O and half-maxi- 
mal saturation concentration, S05 = 10 PM) and arachidonate with co-operativity hat increased with arachi- 
donate concentration (h increasing from - 2 to - 4). S, 5 of arachidonate was 1.5 PM. Arachidonate binding 
to the protein was accompanied by its oligomerization. 
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1. INTRODUCTION 
Exogenous arachidonic acid (5,8,11,16eicosate- 
traenoic acid) aggregates blood platelets of a 
number of species but the response follows a bell- 
shaped pattern, higher concentrations becoming 
progressively more inhibitory to the aggregation by 
lower concentrations [l-4]. Inhibition takes effect 
apparently without damage to platelets and 
without impairment of arachidonic acid metab- 
olism [5] but without having recourse to meta- 
bolic conversion of arachidonic acid [2,3,5,6] 
although 12-hydroperoxyeicosatetraenoic a id, a 
lipoxygenase product, is an inhibitor [4]. The 
biochemical mechanism of the direct inhibitory ef- 
fect is not clear but the recent observation of 
Huang and Detwiler [6] that arachidonic acid 
directly antagonized platelet activation by the 
stable synthetic prostaglandin endoperoxide 
analogue, (1 SS)-hydroxy-1 la,9a-epoxymethano- 
52,13&dienoic acid (U-46619), raised the possibil- 
ity of involvement of an endoperoxide receptor. 
Since peroxide-binding proteins are usually 
haemoproteins we looked for a haemoprotein, 
distinct from the arachidonate cycle-oxygenase, 
which could bind arachidonate as well as U-46619 
in platelets. Here we describe for the first time, the 
purification of such a haemoprotein from calf 
platelets. 
2. MATERIALS AND METHODS 
2.1. Materials 
Sephadex gels were from Pharmacia, Sweden. 
Arachidonic acid, a product of Sigma, was dis- 
solved in absolute alcohol and its concentration 
estimated spectrophotometrically using pJ” 
4750 M-‘*cm-’ [7]. U-46619, a product of Up- 
john, Kalamazoo, MI, obtained through the 
courtesy of Dr J. Lakshmanan, of the University 
of California, Torrance, was dissolved in absolute 
ethanol and its concentration in experimental 
systems was estimated using Eg5 10000 M-’ -cm-’ 
in alcohol, arbitrarily, for the sake of consistency 
in different experimental situations. 
2.2. Preparation of platelets 
Calf (male) blood (100 ml) was collected by 
jugular venic puncture into acid-citrate-dextrose 
solution (15 ml) and the platelets were purified by 
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an adaptation of the method described by Thomp- 
son et al. IS]. The concentration of bovine serum 
albumin was reduced to one tenth that used by 
them. Platelet-rich plasma was prepared by dif- 
ferential centrifugation at 32°C and 100 x g (rav. 
10 cm) for 1 h. Platelets were pelleted from the 
platelet-rich plasma by centrifugation at 32°C and 
450 x g (rav. 10 cm), washed twice in the buffer 
system of Thompson et al. [8], modified as above, 
and resuspended in 100 ml of the non-colloidal 
buffer system of Tangen et al. [9]. 
2.3. Purification of platelet haemoprotein 
Purified platelets (20 ml) were broken 
ultrasonically at 20°C and centrifuged for 30 min 
at 4°C and 12000 x g (ray. 8 cm) to obtain a crude 
extract. The crude extract (110 ml, A405 = 2.3) was 
precipitated with (NH&S04 at 4°C and the second 
fraction, precipitating between 0.5-0.9 saturation 
was collected by centrifugation at 12000 x g for 
30 min and dissolved in 2 ml of 0.05 M sodium 
phosphate buffer (pH 7.4) (referred to hereafter as 
the buffer) and clarified by centrifugation. The 
clear supernatant (A405 - 1.1) was applied to a col- 
umn of Sephadex G-200 (1.2 x 50.5 cm) 
equilibrated with the buffer at 4°C. The column 
was eluted at a flow rate of 13 ml. h-’ and 
haemoprotein fractions, followed by absorbance 
at 405 nm, eluting between 31-50 ml were pooled 
(A405 - 0.8) and precipitated with solid (N&)2s04 
added to 0.95 saturation at 4°C. The protein 
precipitated overnight was collected by centrifuga- 
tion and dissolved in 1 ml of the buffer, and 
dialyzed against the same buffer for 6 h at 4°C. 
The dialysis residue was applied to a column (1.1 
x 28.5 cm) of DEAE Sephadex A-50 equilibrated 
and eluted with the buffer at 4°C and at a flow rate 
of 13 ml-h-‘. The haemoprotein fractions 
(15-24 ml) were pooled, precipitated with 
(NH&S04 dissolved in 1 ml, dialyzed against the 
buffer, and used for the studies reported here. 
3. RESUI-TS 
The purification procedure described here 
resulted in a preparation (1 ml, -440s = 0.12) hav- 
ing 75 bg protein compared to the 12000 x g super- 
natant (110 ml, A405 = 2.3) containing 46 mg of 
protein estimated by the method of Lowry et al. 
[IO]. The elution volume of the haemoprotein 
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from the column of Sephadex G-200 when com- 
pared to those of globular proteins of known M, 
corresponded to an && of 40000. SDS- 
polyacrylamide gel electrophoresis (PAGE) gave a 
major band at &Zf = 21000 (fig.1). The same 
subunit M, was obtained under nonreducing condi- 
tions also showing that two apparently identical 
subunits were held together by noncovalent forces. 
Minor bands were also seen at M, = 42000 and 
-82000 in the gel. 
The purified protein showed Soret maximum at 
405 nm (&,M - 65 mM_’ *cm-‘) which upon 
reduction with Na2S204 shifted to 424 nm (&M - 
40 mM_’ -cm-‘) suggesting the haem iron to be in 
the + 3 oxidation state. 
Treatment of the protein with arachidonate 
shifted its Soret band to 410 nm (fig.ZA). The 
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Fig.1. SDS-PAGE pattern of purified calf platelet 
haemoprotein. The protein (14Opg) in 2 ml of 0.05 M 
sodium phosphate buffer (pH 7.4), was concentrated 
nearly to dryness by dialysis against solid Sephadex 
G-25. It was then dialyzed against distilled water for 1 h 
and the dialysis residue was taken up in the sample 
buffer for electrophoresis in 10% cylindrical gels 
according to the Sigma Technical Bulletin MWS-877 at 
32°C with A#, marker proteins in separate gels. The 
destained gel was scanned at 600 nm in a Shimadzu 
UV-240 spectrophotometer using its gel-scanner 
attachment. The marker proteins employed (with their 
log M, values in parentheses) were: lysozyme (4.16), 
pepsin (4.54), ovalbumin (4.65), and bovine serum 
albumin (4.82). 
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Fig.2. (A) Effect of arachidonic acid on the aerobic 
electronic absorption spectrum of platelet 
haemoprotein. Purified caIf platelet haemoprotein. in 
0.05 M sodium phosphate buffer @H 7.4), having the 
solid line spectrum was treated with a 1 pl sample of 
arachidonic acid in ethanol and the spectrum recorded 
again (broken line), at 35°C. The final arachidonic acid 
concentration was 8.4 pM. (B) A difference absorption 
spectrum obtained after adding arachidonic acid 
(7.5 PM) to the purified plateiet haemoprotein in 0.05 M 
sodium phosphate buffer (pH 7.4) at 35°C. Protein 
sample (1 ml, A405 = 0.07) was taken in each of a pair 
of matched spectrophotometric cuvettes (pathiength 
10 mm) and the base-line was corrected automatic~Iy, 
and recorded. A 1 /rl sample of arachidonic acid in 
ethanol was added to the sample cuvette while 1~1 
ethanol was added to the reference cuvette. The 
spectrum was recorded 5 min after mixing. 
shifted band remained quite stable. A difference 
spectrum of the arachidonate-treated protein 
against the untreated protein showed a peak at 
420 nm and a trough near 402 nm (fig.2B). Gel 
filtration of the ~achidonate-treated protein, in a 
column of Sephadex G-25, reverted the Soret band 
back to 405 nm (not shown). These results showed 
reversible binding of arachidonate to the protein. 
Neither the solvent nor a saturated fatty acid, 
stearic acid (0.8 FM), could produce a spectral ef- 
fect, but another unsaturated fatty acid, homo-r- 
linolenate (8,11,14-eicosatrienoate, Sigma), yet 
another, apparently direct, inhibitor of 
U-46619-induced platelet aggregation [6], did show 
spectral effects similar to arachidonate (not 
shown). 
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Fig.3. (A) Variation of AA(420-402) as a function of 
arachidonate concentration. (B) Hill plot of the data. 
Experimental conditions were those of fig.2B except for 
the use of a freshly prepared solution of arachidonic acid 
in 100 mM NazCO,, the variation in arachidonate 
concentration and the employment of a lower 
tem~rature, 32°C. The total volume of arachidonate 
solution added did not exceed 10~1. 
The magnitude of the difference spectral change 
induced by arachidonate was dependent on the 
concentration of arachidonate (fig.3A) and a Hill 
plot showed two linear regions with Hill coeffi- 
cient, h -2 at low arachidonate concentrations, in- 
creasing to -4 at higher concentrations (fig.3B). 
Thus the degree of positive co-operativity (h > 1) 
of arachidonate binding to the protein increased as 
the arachidonate concentration increased. The 
concentration of arachidonate at half-maximal 
saturation was 1.5 PM under the test conditions. 
An h > 2 was unexpected for a dimeric protein. 
But it was found, in a large-zone gel exclusion 
chromatographic experiment, that treatment of the 
protein (1 ml, A4as = 0.05) with arachidonate 
(7.5aM) reduced its elution volume, from 4.8 to 
4 ml, in a Sephadex G-200 column (0.6 x 17 cm), 
at 5°C. This arachidonate-induced oligomerization 
of the protein, could account for the high degree of 
co-operativity. 
Difference spectra obtained on adding U-46619 
to the purified protein also showed concentration- 
dependent binding interactions (fig.4). The spectra 
did not reveal any distinct peak but a hump at 
about 428 nm seen at high U-46619 concentra- 
tions. The trough was at 405 nm and a plot of 
(AMOS)-’ against (U-46619)-’ was linear (fig.5). A 
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Fig.4. Difference spectra obtained on adding different 
concentrations of U-46619 to purified platelet 
haemoprotein. An alcoholic solution of U-46619 was 
mixed with the haemoprotein in 0.05 M sodium 
phosphate buffer (pH 7.4) (1 ml, A405 = 0.087) at final 
U-46619 concentrations of 3.3pM (curve I), 14.8pM 
(curve 2) and 33 PM (curve 3) and the difference spectra 
were recorded at 32°C as described under fig.ZB, except 
for the use of U-46619 solution, the total volume of 
which did not exceed 15 ~1. Curve 4 was the positive part 
of curve 3 recorded at 2 x expanded scale to show the 
position of the hump. 
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Fig.5. Double reciprocal plot and Hill pIot (inset) of a set 
of data relating the magnitude of spectral change 
obtained at 405 nm (A&5) at various U-46619 
concentrations. Experimental conditions were those of 
fig.4. 
Hill plot of the data was also linear (fig.5, inset) 
with h equal to unity, suggesting that the binding 
interaction was devoid of co-operativity. Half- 
maximal saturation concentration of U-46619 was 
10 PM. 
4. DISCUSSION 
The SDS-PAGE pattern of the purified 
haemoprotein showed a major band corresponding 
to M, = 21000. But it also showed minor bands at 
M, = 42000 and -82000. Since the M, of the 
pooled fractions from the Sephadex G-200 column 
could not have exceeded -50000 and since 
nondenaturing PAGE of the purified protein at 
pH 7.0 and 8.3 showed only one band (not shown), 
we conclude that the high M, material was derived 
from aggregates formed during its dialysis against 
solid Sephadex to concentrate it for elec- 
trophoresis. This treatment was found to result in 
haem loss and aggregation of the apoprotein. The 
42-kDa and -82-kDa bands could then be derived 
from the dissociation of the aggregated material, 
during SDS treatment. The appearance of the 
bands at iK positions which were integral multiples 
of the subunit molecular mass made this a 
reasonable possibility. But the possible presence of 
a 42-kDa contaminant or associated protein (ac- 
tin!) is not ruled out. 
The platelet preparations used for the purifica- 
tion of the protein had been carefully freed from 
other cell types and adsorbed proteins. So the pro- 
tein originated from platelets. Its soluble nature 
and molecular mass (40 kDa) clearly demarcate the 
protein from the other well-known platelet 
haemoprotein, the arachidonate cycle-oxygenase 
[l 1,121 which is particulate and has a subunit 
molecular mass (-79-85 kDa) vastly in excess of 
that found here [ 13-151. Further, although addi- 
tion of arachidonate to the purified cyclo- 
oxygenase produced a spectral shift (409 to 
412 nm), the stability of the shifted Soret band 
observed here was in sharp contrast to its rapid 
destruction in the case of the cycle-oxygenase [ 121. 
But the oxidation state of the haem iron and the 
millimolar absorbance of the Soret bands of the 
two proteins seem to be similar [ll] and the two 
proteins lose their haem prosthetic group quite 
easily. 
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The ability of the protein to bind U-46619 made 
it a likely candidate for being the proaggregatory 
endoperoxide receptor. The following results pro- 
vided additional support to this conclusion. PGG2 
or PGHz, prepared by the method of Hamberg et 
al. [16], on adding to the protein, yielded dif- 
ference spectra having peaks at 425 or at about 
427 nm (in the case of PGH2) and troughs at 
405 nm, suggesting their binding to the protein. 
Prior treatment of these labile compounds with 
water or methanol, known to destroy the en- 
doperoxide group, abolished their ability to bring 
about the characteristic spectral change. This 
result suggested that it was the intact endoperoxide 
molecules themselves, rather than some of their 
decomposition products, that were responsible for 
the binding. The binding of U-46619 to the protein 
was found, by circular dichroism measurements, 
to result in a dose-dependent decrease in the cy- 
helical content of the protein (unpublished), show- 
ing that it did bring about a conformational 
change although there was no suggestion of co- 
operativity in the Hill plot. It was found, further, 
that imidazole, another haem ligand, could induce 
positive co-operativity in the binding of U-46619 to 
the protein and hinder the binding of arachidonate 
to it by noncompetitive type of mechanisms; and 
true to expectation, imidazole enhanced the rates 
of aggregation of gel-filtered calf platelets by 
U-46619 (unpublished). And 8,11,14- 
eicosatrienoate which, like arachidonate, is a direct 
inhibitor of U-46619-induced platelet aggregation 
[6], did indeed bind to the protein while stearic 
acid, not known to affect platelet aggregation, did 
not. 
We envisage the haemoprotein receptor, which 
we have found in the platelets of such widely dif- 
ferent species as calf, sheep and human, to be posi- 
tioned somewhere near the cytoplasmic side of the 
plasma membrane of the platelet dense tubular 
system where the cycle-oxygenase is located 
[ 17,181. The cycle-oxygenase products, PGG2 and 
PGHz, have free access to the receptor as well as 
to the membranous thromboxane A2 synthetase, 
possibly also a haemoprotein [19], whose half- 
maximal saturation concentration is, apparently, 
higher than that of the endoperoxide receptor. The 
receptor, upon interaction with the endoperoxides, 
undergoes a conformational change, triggering the 
platelet activation cascade. In case there is a surfeit 
of arachidonate, or an analogous unsaturated fatty 
acid, it could overflow directly to the endoperoxide 
receptor, resulting in its allosteric alteration and 
making it less amenable to the proaggregatory en- 
doperoxides. This is, apparently, the molecular 
mechanism of the direct antiaggregatory effect of 
exogenous arachidonate, and some other un- 
saturated fatty acids, on platelets. 
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